Lake Street Capital Increases Envoy Medical (NASDAQ:COCH) Price Target to $6.00

Envoy Medical (NASDAQ:COCH) had its price objective increased by equities researchers at Lake Street Capital from $3.00 to $6.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price target points to a potential upside of 2.39% from the stock’s previous close.

Separately, Northland Securities assumed coverage on Envoy Medical in a research note on Thursday, December 21st. They issued an “outperform” rating on the stock.

Envoy Medical Trading Up 6.9 %

COCH opened at $5.86 on Wednesday. Envoy Medical has a 52 week low of $0.75 and a 52 week high of $11.72. The company has a fifty day moving average price of $3.57.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Envoy Medical stock. Weiss Asset Management LP acquired a new stake in shares of Envoy Medical, Inc. (NASDAQ:COCH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the company’s stock, valued at approximately $37,000. Weiss Asset Management LP owned about 0.10% of Envoy Medical at the end of the most recent quarter. 8.59% of the stock is owned by institutional investors.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices, such as auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.